Patient-derived tumor organoids are providing more physiologically relevant models for studying cancer biology and evaluating therapeutic responses than many conventional preclinical systems. When combined with high-content imaging and artificial intelligence (AI)-driven image analysis, these models enable large-scale phenotypic profiling that can reveal novel drug mechanisms and accelerate compound discovery.
In this webinar, Christophe Deben will discuss how high-throughput phenotypic drug screening, AI-driven image analysis, and de novo compound design are being integrated with patient-derived tumor organoids to support small molecule drug discovery and precision oncology research.
Topics to be covered:
- How patient-derived tumor organoids support phenotypic drug screening
- The use of high-content imaging and AI for phenotypic profiling
- Identifying small molecules with novel mechanisms of action
- Integrating organoids, AI, and de novo compound design to advance precision oncology research
This discussion provides a preview of Advances in Immuno-Oncology 2026, where experts from industry and academia will share the latest research and developments in cancer immunology, immunotherapy, and translational oncology. The symposium will explore emerging approaches to better understand cancer biology and advance new strategies for improving patient outcomes.
Thursday, August 20th 2026 | 11:00 AM – 12:00 PM Eastern Time
This webinar will be available to view live and on demand.
Speaker
Christophe Deben, PhD
Professor
University of Antwerp